Know Cancer

forgot password

Perioperative Administration of Desmopressin to Subjects With Breast Cancer: A Phase IIa, Dose-Escalation Study

Phase 2
21 Years
60 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

Perioperative Administration of Desmopressin to Subjects With Breast Cancer: A Phase IIa, Dose-Escalation Study

Breast cancer is one of the most commonly diagnosed malignancies among women, and its
mortality is related to the capacity of tumor cells to invade and produce metastases. It is
postulated that tumor manipulation during surgery results in the release of tumor cells into
circulation or the lymphatic system, and that these released cells survive due to
aggregation among them or with platelets through the formation of a fibrin layer on the
embolus. Tumor cells surviving transportation through circulation will join blood vessels
and invade vascular walls, forming metastases. The interruption of this process might reduce
survival of tumor cells and thus the formation of metastases from breast cancer cells in the
lungs or other tissues.

Inclusion Criteria:

- a. Female subjects from 21 to 60 years of age, who have voluntarily signed the
informed consent form.

b. Histological/cytological diagnosis of breast carcinoma obtained at least 21 days
before inclusion into the study.

c. Candidate for radical mastectomy and requiring resection of axillary lymph nodes
or sentinel node.

d. In case of women of childbearing potential, an adequate birth control method
(intrauterine device, barrier methods, or tubal ligation) should be used throughout
the study. Post-menopausal women should have menopause confirmed by biochemical

e. Adequate organic function, defined by the following parameters:

- Electrocardiogram (ECG) with no significant anomalies, performed within 14 days
prior to surgery.

- The following laboratory results, obtained 7 days before surgery:

- Hemoglobin ≥ 11 g/dL

- Total white blood cell count ≥ 4,000/mm3

- Total neutrophil count 1,500/mm3

- Platelet count within normal limits

- Total bilirubin ≤1.5 x UNL or 2.5 x UNL in case of hepatic metastasis

- Transaminases ALT/GPT and AST/GOT ≤ 1.5 x UNL

- Creatinine clearance >50 mg/dL

- CT scan with oral and endovenous contrast* of chest, pelvis, and abdomen, and
bone scan, conducted within 28 days prior to surgery. Images taken not longer
than 90 days before surgery are also acceptable.

- In case contrast is contraindicated, CT with no contrast or MRI will be

f. Subject with performance status (ECOG) = 0.

Exclusion Criteria:

- a. Synchronic bilateral breast cancer. b. Symptoms of metastasis or evidence of
metastasis from images: chest spiral CT scan, abdomen/pelvis spiral CT scan, brain
spiral CT/MRI (in case of brain metastasis signs), and bone scan.

c. The patient is pregnant or breastfeeding. d. The patient is presently using
hormonal contraceptives or under hormonal treatment. She would be eligible if oral
contraceptives were discontinued or if the hormonal treatment finished 30 days before
surgery and the patient agreed to use another contraceptive method.

e. Patients with a history or presence of congestive heart failure, blood
hypertension, angina pectoris or heart arrhythmia, thromboembolic disease, diabetes
type I or II, or any underlying coronaropathy detected in pre-surgical evaluations.

f. Mentally-impaired patients. g. Patients with known hypersensitivity to DDAVP or
vasopressin, o with severe von Willebrand's disease (VWD), defined by a VWF activity
<10%IU/dL, or type 2B VWD, defined by an increased ristocetin-induced platelet
aggregation (RIPA) at low concentrations of ristocetin or with hemophilia.

h. Patients with a history of seizures. i. Patients with renal impairment (creatinine
clearance < 50 mL/min calculated by the Cockcroft-Gault formula), hyponatremia or
with a history of hyponatremia.

j. Patients with syndrome of inadequate secretion of antidiuretic hormone. k.
Patients with positive serology for the hepatitis B or C virus and/or HIV. l.
Patients with known hepatic disease (diagnosed cirrhosis, hepatic enzymes (GOT/GPT) >
1.5 x UNL, Total bilirubin > 1.5 x UNL).

m. Patients with active infections. n. Patients with other malignant diseases, with
the exception of, non-melanoma skin cancer, or cervix cancer in situ, or any other
tumor that has received adequate treatment and shows a disease-free time ≥ 5 years.

o. Patients participating in another clinical study or cases in which less than 4
weeks have elapsed since participation in another clinical study.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Outcome Measure:

Selection of the higher safe dose level for ensuing clinical trials

Outcome Description:

One of the three dose levels assessed in this study will be selected for further clinical testing in adults: 0,50 mg, 1,0 mg, 1,25 mg, 1,5 mg or 2,0 mg.

Outcome Time Frame:

Up to 2 years

Safety Issue:


Principal Investigator

Dra. Ruth Weinberg

Investigator Role:

Principal Investigator

Investigator Affiliation:

Hospital Interzonal General De Agudos Eva Peron


Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica

Study ID:




Start Date:

November 2011

Completion Date:

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms